Trial reportBiological trace element research2026
The Effect of Chromium Picolinate Supplementation on Cardiometabolic Biomarkers, Tumor Necrosis Factor-α Gene Expression, and DNA Damage in Subjects with Metabolic Syndrome: a Randomized Placebo-Controlled Clinical Trial.
Trial report in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Metabolic Syndrome (MetS) is a complex disorder characterized by metabolic dysregulations. While chromium picolinate (CrPic) has shown beneficial effects on metabolic parameters, its comprehensive effects and safety in MetS patients remain unclear. This study aimed to investigate the effectiveness of CrPic supplementation on cardiometabolic indicators, DNA damage, and inflammatory markers in MetS patients. In this 12-week randomized, double-blind, placebo-controlled trial, 48 subjects with MetS (based on NCEP ATP III criteria) were randomized to receive either 400 µg CrPic daily (n = 24) or placebo (n = 24). Primary outcomes included glycemic control (fasting blood sugar, HbA1c), lipid profile, DNA damage index (8-hydroxydeoxyguanosine), and inflammatory markers (tumor necrosis factor-α (TNF-α) level and gene expression). Secondary outcomes were anthropometric measures and blood pressure. Forty participants (20 in each group) completed the study. CrPic supplementation significantly improved HbA1c (-0.68%, P = 0.005), HDL-c (+ 4.8 mg/dl, P = 0.008), and SBP (-4.8 mmHg, P = 0.012). After adjusting for confounding factors, improvements in HbA1c (-0.07 ± 0.02%, P = 0.001) and SBP (-8.84 ± 3.57 mmHg, P = 0.019) remained significant compared to placebo. CrPic showed no adverse effects on DNA damage markers or inflammatory cytokine expression. CrPic supplementation appears to be a safe intervention that can modestly improve glycemic control, HDL-c levels, and blood pressure in MetS patients. While these improvements were statistically significant, achieving clinically meaningful changes may require optimization of dosage and intervention duration.
Indexed as
Identifiers
41840296What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.